, Volume 19, Issue 5, pp 323–325 | Cite as

Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis

  • David Murdoch
  • Katherine A. Lyseng-WilliamsonEmail author
Adis Spotlight


Subcutaneous recombinant interferon-β-1a (Rebif®) 22 or 44μg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. It has shown benefits on outcome measures related to relapses, progression of disability, and magnetic resonance imaging in clinical trials. A significant efficacy advantage for subcutaneous interferon-β-1a three times weekly over intramuscular interferon-β-1a 30μg once weekly was shown at 24 and 48 weeks. The most common adverse events are generally mild and clinically manageable. Considering both direct and indirect comparative clinical trial data, an assessment suggests that subcutaneous interferon-β-1a 44μg three times weekly has the best benefit-to-risk values of the available disease-modifying drugs used to treat relapsing-remitting multiple sclerosis. 1 This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in Drugs 2005; 65 (9): 1295-312. Reviewers of the original full text article are listed in the Acknowledgments section. 2 The use of trade names is for product identification purposes only and does not imply endorsement.


Expand Disability Status Scale Glatiramer Acetate Glatiramer Rebif Median Treatment Duration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The full text article in Drugs 2005; 65 (9): 1295–312 was reviewed by: C. Gasperini, Department of Neuroscience, S. Camillo-Forlanini Hospital, Rome, Italy; R.M. Herndon, Department of Neurology, G.V. (Sonny) Montgomery Department of Veterans Affairs Medical Center, Jackson, Mississippi, USA; D.D. Miksikostas, Department of Neurology, Athens Naval Hospital, Athens, Greece; H.S. Panitch, Neurology Health Care Service, University of Vermont, College of Medicine, Burlington, Vermont, USA; P.S. Sorensen, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark.


  1. 1.
    Serono, Inc. Rebif (interferon-beta-1a) sc injection: prescribing information. Rock-land (MA): Serono, Inc., 2004Google Scholar
  2. 2.
    Liberati AM, Horisberger MA, Palmisano L, et al. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-β. J Interferon Res 1992; 12(5): 329–36PubMedCrossRefGoogle Scholar
  3. 3.
    Liberati AM, Garofani P, De Angelis V, et al. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J Interferon Res 1994; 14(2): 61–9PubMedCrossRefGoogle Scholar
  4. 4.
    Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002 Apr 23; 58(8 Suppl. 4): S3–9PubMedCrossRefGoogle Scholar
  5. 5.
    Zhang J, Hutton G, Zang Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther 2002 Dec; 24(12): 1998–2021PubMedCrossRefGoogle Scholar
  6. 6.
    Randomised double-blind placebo-controlled study of interferon β-la in relapsing/ remitting multiple sclerosis: PRISMS (Prevention of Relapses and disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352 (9139): 1498-504Google Scholar
  7. 7.
    Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002 Nov 26; 59(10): 1496–506PubMedCrossRefGoogle Scholar
  8. 8.
    Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing MS: the EVIDENCE study. Arch Neurol 2005 May; 62(5): 785–92PubMedCrossRefGoogle Scholar
  9. 9.
    PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001 Jun 26; 56 (12): 1628-36Google Scholar
  10. 10.
    Sorensen PS, Ross C, Clemmesen KJ, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003 Oct 11; 362(9391): 1184–91PubMedCrossRefGoogle Scholar
  11. 11.
    Vartanian TK, Zamvil SS, Fox E, et al. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 2004 Dec 14; 63(11 Suppl. 5): S42–9PubMedCrossRefGoogle Scholar
  12. 12.
    Buchwalder PA, Buclin T, Trinchard I, et al. Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers. J Interferon Cytokine Res 2000 Oct; 20(10): 857–66PubMedCrossRefGoogle Scholar
  13. 13.
    Paty D. Long-term observational efficacy and safety follow-up of the PRISMS cohort [abstract no. P555 plus poster]. 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2003 Sep 17–20; MilanGoogle Scholar
  14. 14.
    Rieckmann P, O’Connor P, Francis GS, et al. Haematological effects of interferon-β-1a (Rebif) therapy in multiple sclerosis. Drug Saf 2004; 27(10): 745–56PubMedCrossRefGoogle Scholar
  15. 15.
    Francis GS, Grumser Y, Alteri E, et al. Heptatic reactions during treatment of multiple sclerosis with inteferon-β-1a: incidence and clinical significance. Drug Saf 2003; 26(11): 815–27PubMedCrossRefGoogle Scholar
  16. 16.
    Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler 2004 Jun; 10(3): 298–301PubMedCrossRefGoogle Scholar
  17. 17.
    Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the β-interferons for MS: a comparison between the three products. Neurology 2004 Feb 24; 62(4): 628–31PubMedCrossRefGoogle Scholar
  18. 18.
    Tremlett H, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol 2004 Nov; 251(11): 1297–303PubMedCrossRefGoogle Scholar
  19. 19.
    Francis GS. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 2004 Sep; 251Suppl. 5: v/42–9Google Scholar
  20. 20.
    Lepen C, Coyle P, Vollmer T, et al. Long-term cost effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis: an econometric model. Clin Drug Invest 2003; 23(9): 571–81CrossRefGoogle Scholar
  21. 21.
    Beresniak A, Coyle P, Vollmer T, et al. Cost-benefit and cost-effectiveness analyses of interferon beta-1a therapies for multiple sclerosis [abstract no. P414 plus poster]. 13th Annual Meeting of the European Neurological Society; 2003 Jun 14–18; IstanbulGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • David Murdoch
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
    Email author
  1. 1.Adis International LimitedYardleyUSA

Personalised recommendations